Eli Lilly Partners with Blacksmith Medicines in $300mn Seed Funding Deal

  • California-based biotech company Blacksmith Medicines announced on it had secured a multimillion-dollar seed funding deal from Eli Lilly
  • It has entered into a research collaboration with the Indianapolis-based pharmaceutical giant to advance human metalloenzyme targets
  • Blacksmith Medicines is currently developing treatments that target metal-dependent enzymes, which the company says provides several distinct advantages over traditional drug discovery approaches
  • Under terms of the investment agreement, Blacksmith Medicines will be eligible to receive up to $60Mn per target in future research, development and commercialization milestones
  • Blacksmith Medicines is a spin-out firm from Forge Therapeutics, a company focused on the development of novel antibiotics

    Fundamentals Eli Lily

    For this year the company, based inIndianapolis revenue will be around 24,39 billion USD. This is according to the average of the analysts' estimates. This is slightly more than 2019's revenue of 22,32 billion USD.

    Historical revenues and results Eli Lilly plus estimates 2020

    aandelenanalysesEli Lilly

    The analysts expect for 2020 a net profit of 6,89 billion USD. For this year the consensus of Eli Lilly's result per share is a profit of 7,52 USD. The price/earnings-ratio is then 24,73.

    Per share the analysts anticipate on a dividend of 2,99 USD per share. Eli Lilly's dividend yield thus equals 1,61 percent. The average dividend yield of the pharmaceutical companies equals a low 0,16 percent.

    Eli Lilly's market capitalization is based on the number of outstanding shares around 196,66 billion USD. The Eli Lilly stock was the past 12 months quite volatile. Since last January the stock is even 37 percent higher. This year the stock price moved between 117 and 189 dollar.

    Historical stock prices Eli Lilly

    stock price elililly

    Click here for dividend Eli Lilly. At 21.32 the stock trades 4,13 percent lower at 185,94 USD.

    Analist.nl Nieuwsdienst: +31 084-0032-842

    Copyright analist.nl B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.